Heated chemotherapy plus immunotherapy and standard chemo for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new approach for locally advanced stomach cancer. It uses a heated chemotherapy bath (HIPEC) before giving a combination of two chemotherapy drugs (SOX or XELOX) plus an immunotherapy drug called serplulimab. This aims to shrink the tumor and improve the chances of successful surgery and long-term control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that is HER2-negative (a certain type).
- Your cancer is locally advanced (it has grown into or through the stomach wall and may have spread to nearby lymph nodes, but not to distant organs).
- You have not had any previous treatment for this cancer (like chemotherapy, radiation, or immunotherapy).
- You are generally in good health (able to do daily activities) and have adequate heart, liver, kidney, and blood function.
- You do not have serious heart problems, autoimmune diseases, or infections like HIV, hepatitis B or C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of chemotherapy that is heated and delivered directly into the belly during surgery (called HIPEC). It uses two drugs, cisplatin and paclitaxel, and is for people with stomach cancer who are at high risk of the cancer returning in the lining of the belly.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) as a first treatment for stomach cancer that cannot be removed by surgery. The goal is to see if this combination can shrink the tumor enough to allow surgery later.
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
This trial combines heated chemotherapy directly into the abdomen (HIPEC) with standard chemotherapy and an immunotherapy drug to treat advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
This trial tests a treatment called HIPEC (heated chemotherapy given directly into the abdomen during surgery) for stomach cancer that has spread to the lining of the belly. The goal is to see if this approach can help remove or shrink the cancer and improve outcomes.
Hear when a new Locally Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.